Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Minerva Endocrinol (Torino). 2024 Jun;49(2):182-195. doi: 10.23736/S2724-6507.23.04103-9.
Semaglutide is the second marketed glucagon-like peptide 1 receptor agonist that can be used safely and efficiently in non-diabetic people with excess weight, providing a new milestone in the pharmacological treatment of obesity. This narrative review aims to describe the clinical actions of this new drug in weight management in non-diabetic patients along with possible side-effects and dropout reasons. To accomplish this, the PubMed database was searched to retrieve the most relevant clinical studies published to date on this topic, using the following keywords "semaglutide and obesity". Currently, semaglutide is on the market in two formulations, the once-weekly subcutaneous (s.c.) semaglutide and once-daily oral semaglutide. Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.
司美格鲁肽是第二种上市的胰高血糖素样肽 1 受体激动剂，可安全有效地用于超重的非糖尿病患者，为肥胖症的药物治疗提供了新的里程碑。本综述性叙述旨在描述这种新药在非糖尿病患者体重管理中的临床作用，以及可能的副作用和停药原因。为此，检索了 PubMed 数据库，以获取迄今为止关于该主题的最相关的临床研究，使用的关键词是“司美格鲁肽和肥胖症”。目前，司美格鲁肽有两种制剂上市，每周一次皮下注射（s.c.）的司美格鲁肽和每日一次口服的司美格鲁肽。文献中关于司美格鲁肽的抗肥胖作用的数据可用于药物的两种给药途径，使用 s.c. 途径的研究更为普遍。然而，鉴于其剂量，口服司美格鲁肽可能更具吸引力，且患者更易坚持治疗，但这一领域还需要进一步的研究。
